Olfactory Receptor Proteins - Bioelectronic Nose: Integration of Biotechnology and Nanotechnology - page 49

Table 3.1 Experimental structures of complexes of GPCRs with different types of ligand

Receptor Class/ a

subclass

Year PDB code Resolution (Å) Ligand Type b Conformational state Reference

Bovine rhodopsin R/α 2000 1F88 2.8 11-cis retinal Inverse agonist Inactive Palczewski et al. [ 26 ]

2004 1U19 2.2 11-cis retinal Inverse agonist Inactive Okada et al. [ 78 ]

2011 3PQR 2.8 All-trans retinal Agonist Activated c Choe et al. [ 35 ]

Squid rhodopsin R/α 2008 2Z73 2.5 11-cis retinal Inverse agonist Inactive Murakami and

Kouyama [ 79 ]

Human β2 adrenergic R/α 2007 2RH1 2.4 Carazolol Inverse agonist Inactive Rasmussen et al. [ 27 ]

2008 3D4S 2.8 Timolol Inverse agonist Inactive Hanson et al. [ 80 ]

2010 3NY8 2.8 ICl118551 Inverse agonist Inactive Wacker et al. [ 81 ]

2010 3NYA 3.2 Alprenolol Antagonist Inactive Wacker et al. [ 81 ]

2011 3P0G 3.5 BI-167107 Agonist Activated d Rasmussen et al. [ 29 ]

2011 3PDS 3.5 FAUC50 Irreversible

agonist

Intermediate Rosenbaum et al. [ 82 ]

Activated e

2011 3SN6 3.2 BI-167107 Agonist Rasmussen et al. [ 30 ]

Turkey β1 adrenergic R/α 2008 2VT4 2.7 Cyanopindolol Antagonist Inactive Warne et al. [ 83 ]

2011 2Y00 2.5 Dobutamine Partial agonist Inactive Warne et al. [ 84 ]

2011 2Y04 3.0 Salbutamol Partial agonist Inactive Warne et al. [ 84 ]

2011 2Y02 2.6 Carmoterol Agonist Inactive Warne et al. [ 84 ]

2011 2Y03 2.8 Isoprenaline Agonist Inactive Warne et al. [ 84 ]

2011 2YCW 3.0 Carazolol Inverse agonist Inactive Moukhametzianov

et al. [ 85 ]

2012 4AMI 3.2 Bucindolol Biased agonist Inactive Warne et al. [ 76 ]

2012 4AMJ 2.3 Carvedilol Biased agonist Inactive Warne et al. [ 76 ]

Human A2A adenosine R/α 2008 3EML 2.6 ZM241385 Inverse agonist Inactive Jaakola et al. [ 86 ]

2011 3QAK 2.7 UK-432097 Agonist Intermediate Xu et al. [ 87 ]

2011 2YDO 3.0 Adenosine Agonist Intermediate Lebon et al. [ 88 ]

2011 2YDV 2.6 NECA Agonist Intermediate Lebon et al. [ 88 ]

2011 3REY 3.3 XAC Antagonist Inactive Dore et al. [ 89 ]